- Report
- November 2023
- 30 Pages
Global
From €2311EUR$2,600USD£2,019GBP
€2888EUR$3,250USD£2,524GBP
- Report
- April 2023
- 180 Pages
Global
From €2133EUR$2,400USD£1,864GBP
€2666EUR$3,000USD£2,330GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €1955EUR$2,200USD£1,708GBP
€2444EUR$2,750USD£2,135GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €1955EUR$2,200USD£1,708GBP
€2444EUR$2,750USD£2,135GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €1955EUR$2,200USD£1,708GBP
€2444EUR$2,750USD£2,135GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €1955EUR$2,200USD£1,708GBP
€2444EUR$2,750USD£2,135GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €1955EUR$2,200USD£1,708GBP
€2444EUR$2,750USD£2,135GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €1955EUR$2,200USD£1,708GBP
€2444EUR$2,750USD£2,135GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €1955EUR$2,200USD£1,708GBP
€2444EUR$2,750USD£2,135GBP
- Report
- February 2022
- 210 Pages
Global
From €5332EUR$6,000USD£4,659GBP
€6665EUR$7,500USD£5,824GBP
- Report
- December 2024
- 200 Pages
Global
From €3333EUR$3,750USD£2,912GBP
- Report
- May 2024
- 200 Pages
Global
From €3688EUR$4,150USD£3,223GBP
- Report
- October 2023
- 145 Pages
Global
From €2799EUR$3,150USD£2,446GBP
- Report
- October 2023
- 145 Pages
Global
From €2799EUR$3,150USD£2,446GBP
- Drug Pipelines
- April 2024
- 202 Pages
Global
From €5652EUR$6,360USD£4,939GBP
€7065EUR$7,950USD£6,173GBP
- Report
- February 2024
- 30 Pages
United States
€1600EUR$1,800USD£1,398GBP
€2000EUR$2,250USD£1,747GBP
- Report
- May 2023
- 450 Pages
Global
From €3555EUR$4,000USD£3,106GBP
€4444EUR$5,000USD£3,883GBP
- Report
- April 2023
- 137 Pages
Global
From €5332EUR$6,000USD£4,659GBP
€6665EUR$7,500USD£5,824GBP
- Report
- June 2022
- 120 Pages
Global
From €4221EUR$4,750USD£3,688GBP
- Report
- April 2023
- 115 Pages
Global
From €4221EUR$4,750USD£3,688GBP

The Anti Tumour Necrosis Factor (anti-TNF) market is a subset of the Immune Disorders Drugs market. Anti-TNF drugs are used to treat a variety of immune-mediated diseases, such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. These drugs work by blocking the action of TNF, a protein that is involved in inflammation and tissue destruction. Anti-TNF drugs are generally administered as injections or infusions, and are often used in combination with other medications.
The anti-TNF market is highly competitive, with a number of companies offering products. These include AbbVie, Amgen, Janssen, Merck, Pfizer, and UCB. Each company has its own portfolio of anti-TNF drugs, and they are continually developing new products to meet the needs of patients. Show Less Read more